Amend Surgical has filed a notice of an exempt offering of securities to raise $3,500,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Amend Surgical is raising up to $3,500,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Robert Lane played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Amend Surgical
Amend Surgical leads the biopharmaceutical industry in promoting development of bone healing with NanoFuse, a bone graft substitute and bone void filler. Amend Surgical is dedicated to the discovery, development, and manufacture of breakthrough medical devices. Developing a platform of strong adhesive barriers, our team is focused on solving difficult clinical problems: Barriers and adhesion in the most challenging surgical environments. Offering compelling alternatives to suture and boosting the current standards of care.
To learn more about Amend Surgical, visit http://www.amendsurgical.com/
Company Linkedin Page: https://www.linkedin.com/company/amend-surgical-inc./
Contact:
Robert Lane, President and Chief Executive Officer
844-281-3169
https://www.linkedin.com/in/robby-lane-amendsurgical/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.